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A B S T R A C T
Background: Melioidosis, caused by the Gram-negative bacterium Burkholderia pseudomallei, is an opportunistic
infection across the tropics. Here, we provide a systematic overview of imported human cases in a non-endemic
country over a 25-year period.
Methods: All 55 Dutch microbiology laboratories were contacted in order to identify all B. pseudomallei positive
cultures from 1990 to 2018. A response rate of 100% was achieved. Additionally, a systematic literature search
was performed, medical-charts reviewed, and tissue/autopsy specimens were re-assessed.
Results: Thirty-three travelers with melioidosis were identified: 70% male with a median-age of 54 years. Risk
factors were present in most patients (n= 23, 70%), most notably diabetes (n= 8, 24%) and cystic fibrosis
(n=3, 9%). Countries of acquisition included Thailand, Brazil, Indonesia, Panama, and The Gambia. Disease
manifestations included pneumonia, intra-abdominal abscesses, otitis externa, genitourinary, skin-, CNS-, and
thyroid gland infections. Twelve (36%) patients developed sepsis and/or septic shock. Repeat episodes of active
infection were observed in five (15%) and mortality in four (12%) patients. Post-mortem analysis showed ex-
tensive metastatic (micro)abscesses amongst other sites in the adrenal gland and bone marrow.
Conclusions: The number of imported melioidosis is likely to increase, given rising numbers of (im-
munocompromised) travelers, and increased vigilance of the condition. This first systematic retrospective sur-
veillance study in a non-endemic melioidosis country shows that imported cases can serve as sentinels to provide
information about disease activity in areas visited and inform pre-travel advice and post-travel clinical man-
agement.
1. Introduction
Worldwide, the number of travelers is increasing substantially. 1.3
billion trips were made in 2017, an increase of 5% from the previous
year [1]. Of those travelers, 323 million went to Asia and the Pacific
regions with Southeast Asia facing the highest growth [1]. In addition,
there is a continuous increase in older travelers with clinically sig-
nificant co-existing conditions, such as diabetes, chronic lung, liver- and
kidney disease, and cystic fibrosis as well as patients on immune-sup-
pressing medications [2–4]. Any traveler exposed to contaminated soil
and/or water due to outdoor activities can be infected with the Gram-
negative environmental saprophyte Burkholderia pseudomallei and may
consequently acquire melioidosis [5,6].
Melioidosis is an emerging tropical infectious disease and endemic
in Southeast Asia and Northern Australia [5–7]. New evidence suggests
that B. pseudomallei is more widely present than previously thought;
predicted worldwide human melioidosis cases are 169,000 each year
with a mortality of up to 50% [8]. The incubation period of melioidosis
is generally 1–21 days [9]. However, the disease can also remain latent
for up to 29 years [5]. Disease presentation can vary from skin ab-
scesses to pneumonia and fulminant sepsis and can be acute (85%) or
chronic (11%) [5]. Melioidosis often mimics other diseases (e.g. tu-
berculosis or cancer), has an uncommon presentation in temperate
countries, and can be missed with standard microbiology techniques
[5]. As a result, the disease is frequently misdiagnosed [5,7]. Up to 80%
of patients with melioidosis have an underlying illness that makes them
susceptible to acquire this life-threatening infection [5]. Individuals
with diabetes mellitus, the most common risk factor, which is present in
more than 50% of all patients with melioidosis, have a 12-fold higher
risk to acquire melioidosis compared to non-diabetics [5,10].
Front-line clinicians in non-endemic countries need to be aware that
fever in returning travelers may signal melioidosis [2]. Microbiologists
should be aware of this condition, recognize the characteristics of B.
pseudomallei, and be familiar with the work-up of any oxidase-positive
Gram-negative rod isolated from samples from anyone who has spent
time in an melioidosis-endemic area [11]. This is further underscored
by the classification of B. pseudomallei by the Centers for Disease Con-
trol and Prevention as a Tier 1 Select Agent. Melioidosis therapy con-
sists of a prolonged antibiotic treatment course; an intravenous phase of
two weeks (carbapenem or ceftazidime) followed by an oral eradication
phase of three to six months (trimethoprim–sulfamethoxazole (TMP-
SMX), or amoxicillin-clavulanic acid) depending on disease presenta-
tion [5]. No vaccine for melioidosis is currently available [12]. There-
fore, preventive measures are key to avoiding infection. In Thailand,
Limmathurotsakul et al. attempted to produce evidence-based guide-
lines for the prevention of melioidosis [13]. However, at present, no
advice is generally given to tourists, but this could include measures
targeted at risk groups, such as the use of waterproof shoes when
walking in wet soil, or the advice to stay indoors during periods of
heavy wind and rain [7,14]. Here, we provide the first retrospective
surveillance study of known imported melioidosis cases in a non-en-
demic country, The Netherlands, for a 25-year period.
2. Material and methods
2.1. Identification of cases
A melioidosis case was defined as the presence of an infection as
determined by the primary physician and a confirmed positive B.
pseudomallei culture [7]. Together with the Dutch National Institute for
Public Health and the Environment (RIVM), we identified melioidosis
cases from 1990. The RIVM offers laboratory identification and/or
confirmation of cultured bacteria to all medical microbiological la-
boratories in the country [15]. This procedure consists of multiple
phenotypical tests, fatty acid analysis, 16S rDNA sequence analysis,
matrix-assisted laser desorption ionization time-of-flight mass spectro-
metry (MALDI-TOF), and a species-specific test based on three PCRs
[15]. Furthermore, some melioidosis cases were reported in the weekly
reports of The Netherlands Early Warning Committee of the RIVM.
In The Netherlands disease notification of melioidosis is not man-
datory, in contrast to some other countries such as the United Kingdom.
Therefore, we contacted all microbiology laboratories known by the
Dutch Society for Medical Microbiology (NVVM) and the RIVM. We
asked all Dutch laboratories to perform a systematic search in their
system for any B. pseudomallei positive culture between 2003 and 2018.
Several cases identified by laboratories before 2003 were also accepted
into the analysis. If laboratories were unable to perform a search of the
last 15 years due to data availability or altered laboratory systems, a
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search period shorter than 15 years was accepted. Laboratories that
identified melioidosis cases were asked to complete the standard case
report form of The Netherlands Melioidosis Registry which includes
questions on signs and symptoms, travel history, microbiology, histo-
pathology, radiology, treatment, etc. (Supplementary Table S1). In
addition, we searched Medline, Embase, and Google (Scholar) for re-
ports of human melioidosis cases in The Netherlands published between
January 1985 and December 2018. The following search terms were
applied: ‘melioidosis’ or ‘pseudomallei’ in combination with ‘traveler*’,
‘tourist*’, ‘Dutch’ or ‘The Netherlands’. The literature search included
articles in all languages. Literature references of relevant articles were
examined to identify additional cases. Medical charts were reviewed
and available histology specimens (of eight patients) were re-assessed
by a dedicated clinical pathologist with a long track record in melioi-
dosis research (J.J.T.H.R.) in order to collect complete epidemiologic,
clinical, radiological, and histopathological characteristics of all iden-
tified cases.
2.2. Ethics and statistical analysis
Since the study was retrospective in nature and only involved data
derived from medical records, an exemption from the need for consent
was provided by the Medical Ethics Review Committee of the
Amsterdam UMC, location Academic Medical Center (reference number
W17_470 # 17.543). Under Dutch law, the secondary use of anon-
ymized human tissue specimens is not subject to ethical review or pa-
tient consent, following the “Code of conduct for responsible use of
human tissue” designed by the Federation of Dutch Medical Scientific
Societies in 2011 [16]. Patient's written consent was obtained for
radiological images presented. Statistical analysis was performed using
Prism/R (version 3.5.1). Non-parametric quantitative variables are
presented as median and range.
3. Results
3.1. Case identification
The response rate for the 55 Dutch microbiology laboratories was
100%. Seventeen laboratories identified 25 cases between 2003 and
2018 by tracking positive B. pseudomallei culture results. Seven la-
boratories were unable to retrieve information prior to 2007. Four la-
boratories were able to retrieve cases from more than 15 years ago
(1990, 1994, 1999, and 2002, respectively). Another 15 cases from the
period 1990 to 2018 were identified through the existing informal
registry and network of the RIVM. An extensive literature search from
1985 to 2018 identified another ten cases. Duplicates (n= 20) were
removed. In total, 33 melioidosis patients were included in the study
(Fig. 1).
3.2. Epidemiology and clinical features
Characteristics of returned travelers recorded with a confirmed B.
pseudomallei infection (n= 33) are listed in Table 1. A complete list of
every patient is provided in Supplementary Table S2. The median age of
patients was 54 years (range 21–83). Twenty-three patients (70%) were
male. All patients resided in The Netherlands, except one woman who
was born and lived in Goa, India, and was on holidays in The Nether-
lands when the diagnosis was established (case no. 2 Supplementary
Table S2). Twenty-three patients (70%) had one or more risk factors,
namely diabetes (n=8), smoking (n=7), cystic fibrosis (n= 3), ex-
cessive alcohol consumption (n= 3), chronic kidney disease (n=2),
chronic liver disease (n= 2), chronic obstructive pulmonary disease
(COPD) (n=1), non-Hodgkin lymphoma (n=1), and methotrexate
and prednisone use (n=1).
Most patients acquired the infection in Thailand (52%, n=17)
followed by Brazil (6%, n=2), Australia, Cambodia, Indonesia,
Myanmar, India, and Vietnam (all n= 1; Table 2). Some patients (18%,
n=6) visited multiple countries and therefore the exact country of
Fig. 1. Flow diagram of patient inclusion.
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melioidosis acquisition cannot be determined. Of interest, a 63-year old
male patient developed the disease two weeks after a trip to The
Gambia which is the second known case from this country (case no. 12
Supplementary Table S2) [17,18]. Another patient, an 83-year old fe-
male, developed clinical evidence of melioidosis two years after a trip
to Panama (case no. 29 Supplementary Table S2). Eighteen patients
reported contact with soil or water e.g. one patient showered with
unchlorinated water (case no. 6 Supplementary Table S2). In addition,
two of those eighteen patients reported traumatic injuries; one patient
exhibited hematomas after a collapse and another suffered from a distal
radius fracture after a motorcycle accident. Two patients reported leech
bites before the occurrence of disease symptoms. For full details see
Supplementary Table S2.
The time between onset of symptoms and presentation to the hos-
pital ranged from 1 to 168 days (median 8). Most patients exhibited
fever (n= 20), cough/dyspnea (n=15), and malaise/fatigue (n=13).
Thoracic pain or weight loss was reported in six patients. In total, 29
patients (88%) were admitted to the hospital. Pneumonia, skin and soft-
tissue infection (SSTI), and genitourinary infections (including prosta-
titis) were the most common manifestations of disease occurring in
respectively 58% (n=19), 18% (n= 6), and 18% (n=6) of travelers.
Interestingly, several patients had notable isolated infections; one with
a prostate abscess, two patients with lymphadenitis, and one patient
with an abscess of the chest wall (respectively case no 7, 10, 13, 21
Supplementary Table S2).
Infection was often multi-focal. Twelve (36%) of the patients pre-
sented with or progressed to sepsis and/or septic shock (Table 1, Fig. 2).
Rare disease presentations included melioidosis of the ear, thyroid
gland, adrenal gland, encephalitis and meningitis, and mycotic an-
eurysm (respectively case no. 6, 33, 23, 31 and 30 Supplementary Table
S2).
Fig. 3 provides characteristic computed tomography (CT), positron
emission tomography (PET-CT), and magnetic resonance imaging (MRI)
images, as well as a chest X-ray and an angiography of different foci of
infection in selected patients with melioidosis.
3.3. Microbiology
All 33 identified patients had a positive B. pseudomallei culture.
Specimens most frequently positive were blood (n=17, 52%) and
sputum (n= 14, 42%; Table 3). B. pseudomallei was also isolated from
Table 1
Clinical characteristics of 33 returned travelers with confirmed Burkholderia
pseudomallei infection.
Variablea No. (%) of patients
Baseline characteristics
Male sex 23 (70)
Age yr - median [range] 54 [21–83]
Risk factors 23 (70)
Diabetes 8 (24)
Smoking 7 (21)
Cystic fibrosis 3 (9)
Excessive alcohol consumption 3 (9)
Chronic kidney disease 2 (6)
Chronic liver disease 2 (6)
COPD 1 (3)
Malignancy 1 (3)
Use of immunosuppressive drugsb 1 (3)
Exposure
Environmental exposurec 18 (55)
Traumatic injury (fall, fracture)d 2 (6)
Unknown 15 (45)
Presenting symptoms
Fever 20 (61)
Coughing/dyspnea 15 (45)
Malaise/fatigue 13 (39)
Gastrointestinal symptoms 6 (18)
Myalgia/joint pain 6 (18)
Thoracic pain 6 (18)
Weight loss 6 (18)
Painful urination 5 (15)
Headache 3 (9)
Dysarthria, diminished consciousness, ataxia or double
vision
3 (9)
Days from onset of symptoms to presentation - median
[range]
8 [1–168]
Hospital admission 29 (88)
Foci of infection
Pneumonia 19 (58)
Genitourinary infectione 6 (18)
Skin and soft-tissue infection 6 (18)
Intra-abdominal abscess (liver, spleen, kidney) 5 (15)
Lymphadenitis 4 (12)
Brain infection (abscess, meningitis, encephalitis) 3 (9)
Otherf 6 (18)
Bacteremia 17 (52)
Sepsis and/or septic shock 12 (36)
Treatmentg
Intervention (e.g. drainage of abscess, bronchoscopy) 21 (64)
Days of antibiotic treatment total – median [range] 99 [26–308]
Days of antibiotic treatment IV - median [range] 18 [10–266]
Days of antibiotic treatment oral - median [range] 84 [14–252]
Outcome
Days of hospital stay – median [range]h 21 [1–335]
ICU admission 12 (36)
Days of ICU admission 4 [1–24]
Post-infectious sequelaei 10 (30)
Repeat episodes of infection 5 (15)
Mortality 4 (12)
a Patients could have multiple risk factors, exposures, presenting symptoms
and foci of infection. For patients who had repeat episodes of infection all
variables were summed. For a complete overview see Supplementary Table S2.
b One patient used both methotrexate and prednisone.
c Environmental exposure pertains water and soil exposure.
d Two patients had environmental exposure and traumatic injury.
e Genitourinary infection contained three patients with prostatitis (9%).
f Other foci of infection in patients were bone marrow and adrenal glands
(n=1), bilateral otitis externa (n= 1), mycotic aneurysm (n= 1), poly-
arthritis (n= 1), and the thyroid gland (n= 1).
g Initial intensive intravenous therapy consisted of ceftazidime (n=22),
meropenem (n=9) or imipenem (n= 1) followed by subsequent eradication
therapy with oral amoxicillin/clavulanic acid (n= 8), TMP-SMX (n=21),
and/or doxycycline (n= 8) to prevent recrudescence or relapse of the disease.
h One patient was admitted 60 days in the hospital and 275 days in a re-
habilitation centre.
i Several patients developed severe post-infectious sequelae, including acute
kidney failure requiring dialysis, intravenous catheter-associated candidemia,
critical illness neuropathy requiring prolonged rehabilitation, and purpura
fulminans following severe necrosis of fingers and toes requiring amputation
and prolonged rehabilitation (all n= 1).
Table 2
Country of acquisition of melioidosis by 33 returned travelers.
Country of acquisition* No. (%)
Thailand 17 (52)
Brazil (Ceara state)a 2 (6)
Australia (North and South) 1 (3)
Cambodia 1 (3)
The Gambia 1 (3)
India (Goa) 1 (3)
Indonesia 1 (3)
Myanmar 1 (3)
Panama 1 (3)
Vietnam 1 (3)
Multiple countries visited on tripb 6 (18)
For a complete overview see Supplementary Table S2.
a One patient, earlier reported in the literature [19], acquired the
infection two days after an eight-day travel in Brazil (Ceara state),
fifteen years before the patient traveled to Vietnam.
b China, Indonesia, Malaysia, Nepal, Thailand, Vietnam.
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bronchoalveolar lavage fluid (BALF; n= 7), genitourinary samples in-
cluding prostate biopsies (n= 6), SSTI derived pus (n=6), lymph node
aspirates or biopsies (n=4), intra-abdominal abscesses (n= 2), cere-
brospinal fluid (CSF) (n= 1), ear swab (n=1), pleural fluid (n=1),
and biopsies from the thyroid gland (n= 1).
Thirteen cases were confirmed with 16S rDNA sequencing in com-
bination with classical phenotypical tests, (including API20 NE) and
fatty acid analysis [15]. After 2003, species specific PCRs [15] were
added (n= 12). Two cases before 1996 were only confirmed by clas-
sical phenotypical tests (see Table 3 and Supplementary Table S2 for
details). B. pseudomallei is generally resistant to gentamicin and colistin
(polymyxin E) and susceptible to amoxicillin/clavulanic acid [5]. All
isolates followed these antibiotic patterns except five which showed
resistance to amoxicillin/clavulanic-acid (n= 3, case no. 3, 19 and 27
Supplementary Table S2) and trimethoprim/sulfamethoxazole (TMP-
SMX, n=2, case no. 2 and 17 Supplementary Table S2).
3.4. Treatment and hospitalization
Initial intensive intravenous therapy consisted of ceftazidime
(n=22), meropenem (n=9) or imipenem (n= 1) followed by sub-
sequent eradication therapy with oral amoxicillin/clavulanic acid
(n=8), TMP-SMX (n= 21) and/or doxycycline (n=8) to prevent
recrudescence or relapse of the disease. Median length of antibiotic
therapy was 99 days (26–308), divided by a first period of 18 days
(10–266) of intravenous treatment followed by 84 days (14–252) of
oral treatment (Table 1). Of note, three patients were not empirically
treated with melioidosis-covering antibiotics as initial regimen on
presentation, as these patients died between 2 and 6 days after ad-
mission before melioidosis was diagnosed.
Seven patients experienced severe adverse effects of antimicrobial
agents (TMP-SMX (n=5, respectively case no. 7, 13, 16, 18, and 19
Supplementary Table S2) doxycycline (n=1, case no. 22
Supplementary Table S2), imipenem and meropenem (n=1, case no.
31 Supplementary Table S2)) that warranted using an agent from an-
other antibiotic class. These side effects included severe skin rash,
ataxia, leucopenia/thrombocytopenia, proteinuria, and impaired liver
function (see Supplementary Table S2). The median length of hospital
stay was 21 days (1–335). Twelve patients required intensive care ad-
mission (median 4, 1–24 days) due to multi-organ failure including
need for vasopressors and mechanical ventilation.
Fig. 2. Clinical presentation of returned travelers with melioidosis.
Pneumonia (n= 19, 58%); Genitourinary infection (n=6, 18%)a, Skin and
soft-tissue infection (n=6, 18%), Intra-abdominal abscess (liver, spleen,
kidney) (n=5, 15%), Lymphadenitis (n=4, 12%), Brain infection (abscess,
meningitis, encephalitis) (n= 3, 19%), polyarthritis (n= 1, 3%), Other (n=5,
15%)b, Sepsis and/or septic shock (n=12, 36%)
a Prostate biopsy (n= 3) and urine culture (n=4). Two patients had both a
positive prostate biopsy and a positive urine culture.
b Other foci of infection in patients were bone marrow and adrenal glands,
bilateral otitis externa, mycotic aneurysm, and the thyroid gland (all n= 1).
Please refer to Supplementary Table S2 for details of cases.
Fig. 3. Radiological manifestations of melioidosis in returned travelers. A
(left): Characteristic magnetic resonance imaging (MRI) image of a 46-year old
male showing an area of partly hyper-intense signal intensity in the liver sus-
pected for a liver abscess (case no. 14). A (right): Chest X-ray of the same 46-
year old patient showing extensive bilateral consolidations suspect of bilateral
pneumonia. B (left): Computed tomography (CT) scan of a 21-year old female
with cystic fibrosis showing multiple pulmonary consolidations suspect of lobar
pneumonia and bronchial tree-in-bud opacities (case no. 11). B (right):
Characteristic MRI image of a 49-year old male depicting two brain abscesses
with edema (case no. 9). C (left): 18F-fluorodeoxyglucose (18F-FDG) positron
emission tomography-CT (PET-CT) scan of a 69-year old male; note the med-
iastinal/hilar lymphadenopathy (images of first episode; case no. 3). C (right):
PET-CT image of a 30-year old female revealing intense uptake in the neck on
the left side suspected for a neck abscess with a “cold” area, highly suspicious
for central necrosis (case no. 13). D (left): Aortic angiography of a 61-year old
male showing a mycotic aneurysm of the distal abdominal aorta (case no. 30). D
(right): Characteristic CT scan image with intravenous contrast of a 57-year old
male showing extensive pleural fluid on the right side (case no. 19). See
Supplementary Table S2 for details of cases.
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3.5. Outcome
Overall mortality in this cohort of returning travelers with melioi-
dosis was 12% (n= 4); these patients all suffered from therapy re-
fractory sepsis and died within 4–112 days (median 10) after the start of
symptoms and between 2 and 26 days (median 2) after hospital ad-
mission. Several patients developed severe post-infectious sequelae,
including acute kidney failure requiring dialysis, intravenous catheter-
associated candidemia, critical illness neuropathy requiring prolonged
rehabilitation, and purpura fulminans leading to severe necrosis of
fingers and toes requiring amputation and prolonged rehabilitation.
Repeat episodes of active melioidosis infection were observed in five
patients (15%). One was possibly due to reinfection as this patient
traveled again to Thailand, the country where he had contacted the
disease just four months before (case no. 30 Supplementary Table S2).
The other four cases were due to relapse as no recurrent travel was
reported. Most repeat of active melioidosis infection occurred within
the first year after primary disease display with a median duration of
252 days (28–465).
Three patients underwent autopsy. Fig. 4A–C shows lung, spleen,
liver and bone marrow tissues obtained through autopsy of a 73-year
old female who died after cardiopulmonary resuscitation after seven
days of illness caused by bilateral pneumonia, which was complicated
by septic shock and respiratory insufficiency requiring intubation and
mechanical ventilation (case no. 23 Supplementary Table S2). Autopsy
findings included severe bronchopneumonia with extensive tissue ne-
crosis in both lungs (Fig. 4A), accompanied by metastatic (micro)ab-
scesses in the spleen (Fig. 4B left), liver (Fig. 4B right), bone marrow
(Fig. 4C left), and adrenal glands (not shown). Post-mortem lung tissue
cultures were positive for B. pseudomallei.
Several cases stand out because of their uniqueness or illustrative
history; some of these are highlighted in Textbox 1 (see Supplementary
Table S2).
4. Discussion
This retrospective surveillance study provides a systematic overview
of culture confirmed imported melioidosis cases in a non-endemic
country for a 25-year period. In total, 33 cases were identified, although
this number is probably an underreporting. Clinicians may not be aware
of melioidosis, particularly, if first seen in non-specialized units after a
long latency period and not clearly connected to previous travels.
Moreover, disease manifestations are often nonspecific, especially at an
early stage. This is underscored by our finding that three patients died
before the correct diagnosis was made and thus before the start of ad-
ministration of correct antibiotic regimens. Overall the burden of me-
lioidosis in terms of mortality and morbidity of individual patients af-
fected was substantial, with a case fatality rate of 12%. Moreover, in
30% of the cases, both short- and long-term sequelae were observed
ranging from renal replacement therapy requiring dialysis to long-term
rehabilitation due to amputation of fingers and toes.
In this study, 70% of the patients had one or multiple risk factors for
melioidosis, such as diabetes and cystic fibrosis. This corresponds with
changing traveler patterns wherein individuals with such risk factors
are often able to travel (longer) and to more adventurous holiday
destinations because of improved clinical management [2]. For ex-
ample, the life expectancy of patients with cystic fibrosis is rising and
due to an aging population more senior tourists are traveling. None of
the travelers in this study were HIV-1 positive, which is in line with the
notion that HIV is not a risk factor for the acquisition of melioidosis [5].
Additionally, excessive alcohol consumption (9%) and smoking (21%)
were reported. Smoking has been earlier identified by some as an in-
dependent risk factor for melioidosis [20] and could potentially impair
the host response to invading pathogens and enhance the risk of in-
fection by inhalation [13]. Thirty percent of patients were not known or
diagnosed with a risk factor, indicating that healthy people can also
develop a severe B. pseudomallei infection, which is in line with earlier
reports in both autochthonous cases and travelers [9,21, 22].
Our study further underscores the ability of B. pseudomallei to cause
infection in virtually any organ. To our knowledge, we are the first to
describe an adult patient with a bilateral otitis externa caused by B.
pseudomallei. Additionally, B. pseudomallei infection was identified post-
mortem amongst other sites in the adrenal glands and the bone marrow
(case no. 23 Supplementary Table S2) and in the thyroid gland (case no.
33 Supplementary Table S2). Infections of these organs are rarely re-
ported [10,23–25] and no clinical findings were reported to suggest
involvement of the adrenal and thyroid gland in those patients.
The number of travelers to melioidosis endemic areas is sub-
stantially increasing. Half of the patients in our study had traveled to
Thailand, resonating with Thailand being a popular travel destination
welcoming 236,300 Dutch tourists in the year [26]. It remains chal-
lenging however to determine if the relative high number of melioidosis
cases associated with travel to Thailand is a reflection of a high risk in
that country or simply the number of people who holiday there.
Moreover, we identified patients who traveled to Australia, Brazil [19],
Table 3
Microbiology: identification of Burkholderia pseudomallei in 33 returned tra-
velers.
Culturea No (%)
Positive identification by cultureb 33 (100)
Blood 17 (52)
Sputum 14 (42)
BALF 7 (21)
Genitourinaryc 6 (18)
Skin and soft-tissue derived pus 6 (18)
Lymph node aspirate or biopsy 4 (12)
Intra-abdominal abscessd 2 (6)
Othere 6 (18)
Identification methodology by culturef 33 (100) Confirmed by RIVMg
Methodology not specified 2 (6) 0
API20 NE 10 (30) 15 (45)h
VITEK/Phoenix 8 (24) 4 (12)
MALDI-TOF B. pseudomallei in database 9 (27) 4 (12)
MALDI-TOF B. pseudomallei not in database 5 (15) 2 (6)i
16S rDNA sequencing 8 (24) 13 (39)
Species specific PCR on isolate 3 (9) 12 (36)
Other 0 14 (42)j
Identification methodology non-culture 4 (12) 0
Serology (ELISA) 2 (6)k 1 (3)
Specific PCR on patient tissue (relapse case) 2 (6) 0
Abbreviations: BALF=bronchoalveolar lavage fluid, ELISA= enzyme-linked
immunosorbent assay, MALDI-TOF=matrix assisted laser desorption/ioniza-
tion time-of-flight, RIVM=Centre for Infectious Disease Control, National
Institute for Public Health and the Environment (RIVM), Bilthoven, The
Netherlands.
a Patients could have multiple positive cultures from different sites. For a
complete overview see Supplementary Table S2.
b One patient had a positive culture in Thailand during travels and had a
repeat episode of infection in The Netherlands.
c Prostate biopsy (n= 3) and urine culture (n= 4). Two patients had both a
positive prostate biopsy and a positive urine culture.
d One patient had intra-abdominal abscesses in liver, spleen and kidneys.
e Other locations included cerebro-spinal fluid, ear swab, pleural fluid, bone
marrow biopsy, adrenal gland biopsy and thyroid gland biopsy (all n=1).
f Identification was based on a single method in six cases.
g The RIVM confirmed in total 15 strains by making use of multiple pheno-
typical tests, fatty acid analysis, 16S rDNA sequence analysis, matrix-assisted
laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF), and
PCR based species-specific test [15].
h Phenotypical tests included API20 NE (n=15).
i Two confirmed by a second method [15].
j Other Identification methods included fatty acid analysis (n= 12), and
antiserum agglutination (n= 2).
k Culture confirmed by RIVM (n=1), culture identification by API20 NE not
confirmed by RIVM (n= 1).
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Fig. 4. A selection of histopathological findings
of returned travelers with melioidosis. A-C:
Representative photomicrophotographs (all H&E
stainings) of autopsy specimens from a 73-year old
female patient (case no. 23). A (left): Lung tissue
sample (left lower lobe; original magnification ×4)
showing alveolar parenchyma with signs of severe
suppurative bronchopneumonia. A (right): Higher
magnification (×10) of the same sample, showing
damaged pulmonary architecture due to necrosis of
alveolar septa. B (left): Spleen tissue sample (ori-
ginal magnification ×10) with presence of meta-
static micro abscess and necrosis. B (right): Liver
tissue sample (original magnification ×10) with
presence of intra parenchymatous metastatic micro
abscess. C (left): Bone marrow tissue sample (ori-
ginal magnification ×20) with presence of in-
flammation. C (right): Lymphadenectomy specimen
((original magnification ×20) of the 69-year old
male patient presented in Textbox 1 (case no. 3).
Image shows lymph node tissue with extensive
granulomatous inflammation with areas of confluent
tissue necrosis. See Supplementary Table S2 for de-
tails of cases.
Textbox 1
Two case vignettes
A 55-year old male (case no. 6 Supplementary Table S2) presented with a one-month history of fatigue, subfebrile temperatures not exceeding
38°, and bilateral ear pain after traveling to Thailand (case no. 6 Supplementary Table S2). He was diagnosed with a bilateral otitis externa. His
medical history revealed bilateral otosclerosis and an ear bone chain prosthesis on the right side. Bilateral ear swab cultures grew B. pseu-
domallei, which was confirmed by PCR. CT scan showed no signs of mastoiditis nor any foci in other body parts but did show wall thickening of
the external ear canals. Daily showers with unchlorinated water on the countryside in Thailand might have been the source of infection. The
patient was treated on an outpatient basis and fully recovered on ten days of meropenem via outpatient parenteral antibiotic therapy followed
by three months of oral TMP-SMX.
Another patient, a 69-year old male (case no. 3 Supplementary Table S2) with an unremarkable medical history, was admitted to the
hospital with complaints of coughing, sub-febrile temperatures not exceeding 38°, and 12 kg weight loss after traveling to Thailand seven
months earlier. A PET-CT showed an extensive confluent and abscess like mediastinal lymphadenopathy (Fig. 3C left). Biopsies taken during
mediastinoscopy showed lymph node tissue with extensive granulomatous inflammation with areas of confluent tissue necrosis (Fig. 4C right).
Culture of the pus yielded Gram-negative rods that were initially misidentified as B. thailandensis by MALDI-TOF because the Security Database
was not used. PCR, however, confirmed the microorganism to be B. pseudomallei. He was treated with ceftazidime for two weeks followed by
ten weeks of TMP-SMX. Soon thereafter, the CRP value increased again, and PET/CT-imaging still showed 18F-fludeoxyglucose (FDG) avid
mediastinal lymphadenopathy, despite the patient being asymptomatic. At this time, treatment consisted of meropenem for six weeks followed
by six months of TMP-SMX. Four months after completion of this second prolonged course of antibiotics the CRP levels rose again; meanwhile
the patient remained asymptomatic. Consequently, a transbronchial ultrasound-guided fine-needle aspiration was performed. The cytology
specimen again showed signs of granulomatous inflammation. Whilst cultures remained negative, PCR was positive for B. pseudomallei. CRP
levels normalized spontaneously and it was decided to not treat the patient again but adopt a wait and see policy instead. Currently, 1.5 years
after the second antibiotic course, the patient is in good health.
A complete description of all cases is provided in Supplementary Table S2.
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The Gambia [17], Indonesia, India [27], Myanmar, and Panama. Me-
lioidosis can remain latent up to almost three decades [5] and therefore
relevant travel may have occurred before most recent travel. Recent
studies in sub-Saharan Africa [28,29] and Latin America [30], including
modeling studies [8,31], indicated that melioidosis is more widespread
across the tropics than previously thought. This illustrates that re-
turning travelers with melioidosis serve as sentinels for detecting the
emergence of this disease in tropical countries not yet considered as
endemic and, more importantly, for understanding the global move-
ment of melioidosis across borders [2]. It should be noted that cross-
border movement is not a new phenomenon, as was shown by a recent
sequencing study indicating that B. pseudomallei was already being
spread via trade routes from Australia via Africa to (South) America in
the 17th-19th century [32]. The only well documented example of
transmission of melioidosis to a temperate climate occurred in the mid-
1970s in France. An unexpected outbreak of melioidosis in a zoo in
Paris resulted in the spread to other zoos and equestrians clubs. A
number of animals were culled and at least two humans succumbed
because of melioidosis [33].
Our study has several strengths. Multiple literature studies of me-
lioidosis in travelers have been published [21,22,34,35]; however, to
our knowledge this is the first systematic retrospective surveillance
study in a non-endemic melioidosis country. This is reflected in the
number of cases presented. A recent literature review of melioidosis
cases imported into Europe included 77 patients [34], yet with only
four Dutch cases [34]. Existing surveillance networks such as Geo-
Sentinel and EuroTravNet are powerful tools to gain insights into
travel-related diseases [36]. However, with respect to melioidosis, only
21 cases have been identified within the whole of Europe by the
EuroTravNet in the period 1998–2018 [Grobusch MP. Personal com-
munication EuroTravNet. 15 January 2019]. EuroTravNet includes
traveler's information only derived from institutions whose clinics
(often specialized academic centers) are already linked to the network.
We believe our study can potentially contribute to the further im-
provement and continuous expansion of such networks. Moreover, in
most countries, no advice on melioidosis is given to travelers with
specific risk factors who are going to endemic areas [3,4]. Our study
can contribute to the guidance of clinicians in the provision of such
advice. The first evidence-based guidelines developed in Thailand
propose that protection is required against inhalation, percutaneous
inoculation, and contaminated food or water [13]. The Center for
Disease Control in The Northern Territory of Australia has developed
specific guidelines and advice regarding prevention measures, for ex-
ample, avoiding swimming in fresh water during the rainy season in
endemic areas for various risk groups (diabetes, excessive alcohol
consumption, chronic lung, liver, and kidney disease) [14]. In addition,
the Central Public Health Laboratory in London, United Kingdom, has
formulated a melioidosis specific advice targeted at cystic fibrosis pa-
tients to avoid rural areas in endemic countries, especially during the
rainy season and severe weather events [37]. Nonetheless, given the
extent of global travel, the chance for any individual traveler to acquire
melioidosis remains relatively small.
Several limitations to our efforts should be mentioned. Complete
data capture was challenging because of the retrospective nature of our
study. Furthermore, caution needs to be exercised in interpreting the
rise in numbers over the years as long as denominators remain in-
determinable, and the influence of factors improving the awareness of
melioidosis remain unrecognized. There is a chance that melioidosis
cases might have been missed as seven laboratories were unable to
retrieve information before 2007. Moreover, as culture remains the
gold standard to identify B. pseudomallei infection and has an estimated
sensitivity of ∼60% [5] melioidosis cases might have been passed
undetected. Due to the extended study period, not all laboratory iden-
tification methods were standardized. Of interest, some bacterial iso-
lates showed resistance against amoxicillin/clavulanic acid and TMP-
SMX. However, results should be interpreted with caution as the
European Committee on Antimicrobial Susceptibility Testing (EUCAST)
was only founded in 1997 and at the moment, no EUCAST standards for
the assessment of B. pseudomallei resistance to recommended antibiotic
therapies have been developed [38]. The same holds true for the
Clinical and Laboratory Standards Institute (CLSI) in the US. Acquired
resistance to antibiotics is rare [39], indicating that the resistance rate
we report in our study is likely an over estimation. More studies on B.
pseudomallei antibiotic resistance together with the development of
specific interpretive criteria are needed. Additionally, repeat episodes
of active infection were observed in 15% of cases. Unfortunately, no
sequence typing of bacterial isolates to enable distinction between re-
lapse and reinfection was performed.
5. Conclusions
In conclusion, imported melioidosis is likely to increase in the light
of rising numbers of travelers with a chronic condition (or who are
otherwise immunocompromised), improvements in diagnostics, and
increased vigilance towards the condition. This first systematic retro-
spective surveillance study in a non-endemic melioidosis country shows
that imported cases can serve as sentinels to provide information about
disease activity in areas visited and inform pre-travel advice and post-
travel clinical management.
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